Literature DB >> 12583556

Successful treatment of Candida albicans osteomyelitis of the spine with fluconazole and surgical debridement: case report.

M M El-Zaatari1, K Hulten, Y Fares, A Baassiri, M Balkis, A Almashhrawi, F A K El-Zaatari.   

Abstract

A 65-year old diabetic male presented with progressive bone destruction of thoracic spine (T-11&12) with cord compression. Candida albicans was isolated from aspirated materials pre-and intra-operative. Two weeks of fluconazole was given prior to surgical debridement, and fixation of the lesion. C. albicans isolated pre-and 2-weeks after fluconazole treatment were DNA-typed using AP-PCR. MIC was 2-4 mg/l in all isolates tested. The pre-and post treatment isolates had two DNA patterns, indicating the existence of two different strains. Surgical treatment was necessary for patient recovery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12583556     DOI: 10.1179/joc.2002.14.6.627

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  4 in total

1.  Candida albicans osteomyelitis of the spine: progressive clinical and radiological features and surgical management in three cases.

Authors:  Rabi M Khazim; Ujjwal K Debnath; Youssef Fares
Journal:  Eur Spine J       Date:  2006-01-21       Impact factor: 3.134

2.  Candida parapsilosis spondylodiscitis after lumbar discectomy.

Authors:  Kyungil Cho; Sun-Ho Lee; Eun-Sang Kim; Whan Eoh
Journal:  J Korean Neurosurg Soc       Date:  2010-04-30

3.  Bone-destroying candida infection following left ventricular assist device explant.

Authors:  Osamu Seguchi; Tomoyuki Fujita; Yoshihiro Murata; Masanobu Yanase; Masahiro Higashi; Koichi Toda; Takeshi Nakatani
Journal:  J Artif Organs       Date:  2013-02-20       Impact factor: 1.731

4.  Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011).

Authors:  Maria N Gamaletsou; Dimitrios P Kontoyiannis; Nikolaos V Sipsas; Brad Moriyama; Elizabeth Alexander; Emmanuel Roilides; Barry Brause; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-08-21       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.